Publications
Berends S.E., Steeg T.J.v., Ahsman M.J., Singh S,. Brandse J.F., D’Haens G.R.A.M., Mathôt R.A.A. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. J. Pharmacokinet. Pharmacodyn.: 5, 2019. [Link to publication]
Solms A., Iorio A., Ahsman M. J., Vis P., Shah A., Berntorp E., Garmann D. Favorable Pharmacokinetic Characteristics of Extended ‑ Half ‑ Life Recombinant Factor VIII BAY 94 ‑ 9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. Clin. Pharmacokinet, 2019. [Link to publication]
Snelder N., Heinig R., Drenth H.J., Joseph A., Kolkhof P., Lippert J., Garmann D., Ploeger B., Eissing T. Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clin. Pharmacokinet: 1179-1926, 2019. [Link to publication]
Reinecke I., Hofmann B., Mesic E., Drenth H.J., Garmann D. An integrated population pharmacokinetic analysis to characterize levonorgestrel pharmacokinetics after different administration routes. J Clin Pharmacol: 1639-1654, 2018. [Link to publication]
Betts A., Keunecke A., Steeg T.J.v., Graaf P.H.v.d., Avery L.B., Jones H., Berkhout J. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. MAbs: 1–55, 2018. [Link to publication]
Trame M.N., Riggs M., Biliouris K., Marathe D., Mettetal J., Post T.M., Rizk M.L., Visser S.A.G., Musante C.J. A Perspective on the State of Pharmacometrics and Systems Pharmacology Integration. CPT Pharmacometrics Syst Pharmacol: 617-620, 2018. [Link to publication]
Maanen E.M.T.v., Steeg T.J.v., Ahsman M., Michener M.S., Savage M.J., Kennedy M.E., Kleijn H.J., Stone J., Danhof M. Extending a systems model of the APP pathway: Separation of β- and γ-secretase sequential cleavage steps of APP. J. Pharmacol. Exp. Ther.: 507-518, 2018. [Link to publication]
Facius A., Marostica E., Gardiner P., Watz H., Lahu G. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease. Clin. Pharmacokinet: 1029-1038, 2018. [Link to publication]
Schulthess P., Post T.M., Yates J., Graaf P.H.v.d. Frequency-Domain Response Analysis for Quantitative Systems Pharmacology Models. CPT Pharmacometrics Syst Pharmacol: 111–123, 2018. [Link to publication]
Goto, A., Tagawa, Y., Moriya, Y., Sato, S., Yamamoto, M., Wakabayashi T., Tsukamoto T., Jongh J.d., Steeg T.J.v., Moriwaki T., Asahi, S. Influence of Body Composition on Disposition of the Highly Fat Distributed Compound as Analyzed by Physiologically-based Pharmacokinetic (PBPK) Modeling and Simulation. Biopharmaceutics & Drug Disposition: 543-552, 2017. [Link to publication]